1-20 of 24
Elicia Penuel
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Subcutaneous Mosunetuzumab Leads to High Rates of Durable Responses, Low Rates of Cytokine Release Syndrome, and Non-Inferior Exposure Compared with Intravenous Administration in Patients with Relapsed/Refractory Follicular Lymphoma: Primary Analysis of a Pivotal Phase II

Nancy L. Bartlett, Laurie H. Sehn, Sarit E. Assouline, Pratyush Giri, John Kuruvilla, Stephen J. Schuster, Sung-Soo Yoon, Keith Fay, Georg Hess, Martin Dreyling, Norma C. Gutierrez, Eva Cybulski, Antonia Kwan, Elicia Penuel, Samuel Tracy, Denison Kuruvilla, Joseph Chen, Volker Wiebking, Michael C. Wei, L. Elizabeth Budde
Journal: Blood
Blood (2024) 144 (Supplement 1): 1645.
https://doi.org/10.1182/blood-2024-194612
Published: 2024
Journal Articles

Mosunetuzumab Continues to Demonstrate Clinically Meaningful Outcomes in Patients with Relapsed and/or Refractory Follicular Lymphoma after ≥2 Prior Therapies Including Those with a History of POD24: 4-Year Follow-up of a Pivotal Phase II Study

Mazyar Shadman, Nancy L. Bartlett, Matthew Matasar, Stephen J. Schuster, Sarit E. Assouline, Laurie H. Sehn, John Kuruvilla, Pratyush Giri, Chan Y. Cheah, Sascha Dietrich, Keith Fay, Matthew Ku, Loretta Nastoupil, Michael C. Wei, Shen Yin, Connie Y. Ma, Samuel Tracy, Antonia Kwan, Elicia Penuel, L. Elizabeth Budde
Journal: Blood
Blood (2024) 144 (Supplement 1): 4407.
https://doi.org/10.1182/blood-2024-197897
Published: 2024
Journal Articles

A Randomized Phase II Study of Mosunetuzumab SC Plus Polatuzumab Vedotin Demonstrates Improved Outcomes Versus Rituximab Plus Polatuzumab Vedotin in Patients (Pts) with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL)

Julio C. Chavez, Adam J. Olszewski, Mariana Bastos-Oreiro, Sarit E. Assouline, Izidore S. Lossos, Catherine Diefenbach, Nilanjan Ghosh, Dipenkumar Modi, Waleed Sabry, Seema Naik, Nirav N. Shah, Ronan Foley, Daniel J Hodson, Sneha Makadia, Song Pham, Elicia Penuel, Hao Wu, Wahib S. Ead, Iris To, Connie Lee Batlevi, Michael C. Wei, L. Elizabeth Budde
Journal: Blood
Blood (2024) 144 (Supplement 1): 989.
https://doi.org/10.1182/blood-2024-194581
Published: 2024
Journal Articles

Mosunetuzumab Monotherapy Demonstrates Encouraging Activity and a Manageable Safety Profile in Patients with Heavily Pre-Treated Relapsed or Refractory Mantle Cell Lymphoma

L. Elizabeth Budde, Matthew Matasar, Laurie H. Sehn, Sarit E. Assouline, John Kuruvilla, Ian W. Flinn, Sung-Soo Yoon, Francesc Bosch, Daniel Greenwald, Norma C. Gutierrez, Dimitrios Tzachanis, Paula Marlton, Delaney McGuirt, Shen Yin, Michael C. Wei, Antonia Kwan, Samuel Tracy, Elicia Penuel, Nancy L. Bartlett
Journal: Blood
Blood (2024) 144 (Supplement 1): 1646.
https://doi.org/10.1182/blood-2024-197902
Published: 2024
Journal Articles

Long-term 3-year follow-up of mosunetuzumab in relapsed or refractory follicular lymphoma after ≥2 prior therapies

Clinical Trials & Observations
Laurie H. Sehn, Nancy L. Bartlett, Matthew J. Matasar, Stephen J. Schuster, Sarit E. Assouline, Pratyush Giri, John Kuruvilla, Mazyar Shadman, Chan Y Cheah, Sascha Dietrich, Keith Fay, Matthew Ku, Loretta J. Nastoupil, Michael C. Wei, Shen Yin, Iris To, Derrick Kaufman, Antonia Kwan, Elicia Penuel, Christopher R. Bolen, Lihua Elizabeth Budde
Journal: Blood
Blood blood.2024025454.
https://doi.org/10.1182/blood.2024025454
Published: 2024
Includes: Supplemental data
Journal Articles

Loss of CD20 expression as a mechanism of resistance to mosunetuzumab in relapsed/refractory B-cell lymphomas

Clinical Trials & Observations
Stephen J. Schuster, Ling-Yuh Huw, Christopher R. Bolen, Victor Maximov, Andrew G. Polson, Katerina Hatzi, Elisabeth A. Lasater, Sarit E. Assouline, Nancy L. Bartlett, L. Elizabeth Budde, Matthew J. Matasar, Hartmut Koeppen, Emily C. Piccione, Deanna Wilson, Michael C. Wei, Shen Yin, Elicia Penuel
Journal: Blood
Blood (2024) 143 (9): 822–832.
https://doi.org/10.1182/blood.2023022348
Published: 2024
Includes: Supplemental data
Journal Articles

Baseline CD4 T Cells Are Associated with Improved Response to CD20-CD3 Bispecifics in Lymphoma

Christopher R. Bolen, Sumedha Roy, Ling-Yuh Huw, Katerina Hatzi, Elicia Penuel
Journal: Blood
Blood (2023) 142 (Supplement 1): 3005.
https://doi.org/10.1182/blood-2023-186771
Published: 2023
Journal Articles

Response to Mosunetuzumab in Patients with B-Cell Lymphomas Relapsed or Refractory after CAR-T Cell Therapy Is Associated with Changes in Lymphocyte Counts

Elise A. Chong, Elicia Penuel, Nancy L. Bartlett, Francesc Bosch, L. Elizabeth Budde, Keith Fay, Ian W. Flinn, Andre Goy, Anita Kumar, Rachel Lundberg, Ellen B. Napier, Loretta J. Nastoupil, Mazyar Shadman, Michael C. Wei, Mei Wu, Shen Yin, Emeline R. Chong, Stephen J. Schuster
Journal: Blood
Blood (2023) 142 (Supplement 1): 1752.
https://doi.org/10.1182/blood-2023-190201
Published: 2023
Journal Articles

Novel CD20 Mutations As a Mechanism of Resistance to CD20-CD3 Targeted Therapies in Non-Hodgkin's Lymphoma

Victor Maximov, Christopher R. Bolen, Andrew G. Polson, Elicia Penuel, Elisabeth A. Lasater
Journal: Blood
Blood (2023) 142 (Supplement 1): 2808.
https://doi.org/10.1182/blood-2023-187696
Published: 2023
Journal Articles

Identification of High-Risk Population in First-Line Follicular Lymphoma at Screening with a Next Generation Sequencing (NGS) Assay Using Plasma Circulating Tumor DNA (ctDNA): Initial Data from Gallium

Alessia Bottos, Corinna Woestmann, Christopher R. Bolen, Maria Shin, Patrick Bogard, Ehsan Tabari, Andrew S. Davies, Andrea Knapp, Tina Nielsen, Oliver Weigert, Elicia Penuel
Journal: Blood
Blood (2023) 142 (Supplement 1): 1629.
https://doi.org/10.1182/blood-2023-181723
Published: 2023
Journal Articles

Mosunetuzumab Monotherapy Continues to Demonstrate Durable Responses in Patients with Relapsed and/or Refractory Follicular Lymphoma after ≥2 Prior Therapies: 3-Year Follow-up from a Pivotal Phase II Study

Stephen J. Schuster, Laurie H. Sehn, Nancy L. Bartlett, Matthew Matasar, Sarit Assouline, Pratyush Giri, John Kuruvilla, Mazyar Shadman, Chan Y. Cheah, Sascha Dietrich, Keith Fay, Matthew Ku, Loretta J. Nastoupil, Michael C. Wei, Shen Yin, Iris To, Jiangeng Huang, Antonia Kwan, Elicia Penuel, L. Elizabeth Budde
Journal: Blood
Blood (2023) 142 (Supplement 1): 603.
https://doi.org/10.1182/blood-2023-173692
Published: 2023
Journal Articles

Pharmacodynamic Biomarkers of Mosunetuzumab Efficacy and Safety in Patients with Relapsed/Refractory Non-Hodgkin Lymphoma: Results from a Phase I/II Study

Ling-Yuh Huw, Feifei Li, Anton Belousov, Hemanth Ramesha, Christopher R. Bolen, Michael C. Wei, Shen Yin, David C. Turner, Elicia Penuel
Journal: Blood
Blood (2022) 140 (Supplement 1): 6448–6449.
https://doi.org/10.1182/blood-2022-157934
Published: 2022
Journal Articles

Mosunetuzumab Monotherapy Demonstrates Durable Efficacy with a Manageable Safety Profile in Patients with Relapsed/Refractory Follicular Lymphoma Who Received ≥2 Prior Therapies: Updated Results from a Pivotal Phase II Study

Nancy L. Bartlett, Laurie H. Sehn, Matthew J. Matasar, Stephen J. Schuster, Sarit Assouline, Pratyush Giri, John Kuruvilla, Miguel Canales, Sascha Dietrich, Keith Fay, Matthew Ku, Loretta J. Nastoupil, Michael C. Wei, Shen Yin, Iris To, Huang Huang, Juliana Min, Elicia Penuel, L. Elizabeth Budde
Journal: Blood
Blood (2022) 140 (Supplement 1): 1467–1470.
https://doi.org/10.1182/blood-2022-157691
Published: 2022
Journal Articles

Subcutaneous Mosunetuzumab Is Active with a Manageable Safety Profile in Patients (pts) with Relapsed/Refractory (R/R) B-Cell Non-Hodgkin Lymphomas (B-NHLs): Updated Results from a Phase I/II Study

Elizabeth L. Budde, Nancy L. Bartlett, Pratyush Giri, Stephen J. Schuster, Sarit Assouline, Sung-Soo Yoon, Keith Fay, Matthew J. Matasar, Norma C. Gutierrez, Paula Marlton, Martin Dreyling, Dok Hyun Yoon, Georg Hess, John Radford, Volker Wiebking, Shen Yin, Eva Cybulski, David C. Turner, Huang Huang, Mingzhu Zhou, Elicia Penuel, Michael C. Wei, Laurie H. Sehn
Journal: Blood
Blood (2022) 140 (Supplement 1): 3753–3755.
https://doi.org/10.1182/blood-2022-157729
Published: 2022
Journal Articles

SUNMO: A Phase III Trial Evaluating the Efficacy and Safety of Mosunetuzumab in Combination with Polatuzumab Vedotin Versus Rituximab in Combination with Gemcitabine Plus Oxaliplatin in Patients with Relapsed or Refractory Aggressive B-Cell Non-Hodgkin Lymphoma

Jason Westin, Adam J. Olszewski, Laura Maria Fogliatto, Won-Seog Kim, Ho-Jin Shin, Hao Wu, Shen Yin, Song Pham, Elicia Penuel, Jing Jing, Michael C. Wei, Elizabeth L. Budde
Journal: Blood
Blood (2022) 140 (Supplement 1): 3771–3772.
https://doi.org/10.1182/blood-2022-157710
Published: 2022
Journal Articles

Subcutaneous (SC) Administration of Mosunetuzumab with Cycle 1 Step-up Dosing Is Tolerable and Active in Patients with Relapsed/Refractory B-Cell Non-Hodgkin Lymphomas (R/R B-NHL): Initial Results from a Phase I/II Study

Nancy L. Bartlett, Pratyush Giri, L. Elizabeth Budde, Stephen J. Schuster, Sarit Assouline, Matthew J. Matasar, Sung-Soo Yoon, Miguel Canales, Norma C. Gutierrez, Keith Fay, Chan-Yoon Cheah, Paula Marlton, Volker Wiebking, Shen Yin, Iris To, Chi-Chung Li, Huang Huang, Mingzhu Zhou, Elicia Penuel, Carol O'Hear, Laurie H. Sehn
Journal: Blood
Blood (2021) 138 (Supplement 1): 3573.
https://doi.org/10.1182/blood-2021-147937
Published: 2021
Journal Articles

Mosunetuzumab Monotherapy Is an Effective and Well-Tolerated Treatment Option for Patients with Relapsed/Refractory (R/R) Follicular Lymphoma (FL) Who Have Received ≥2 Prior Lines of Therapy: Pivotal Results from a Phase I/II Study

L. Elizabeth Budde, Laurie H. Sehn, Matthew J. Matasar, Stephen J. Schuster, Sarit Assouline, Pratyush Giri, John Kuruvilla, Miguel Canales, Sascha Dietrich, Keith Fay, Matthew Ku, Loretta Nastoupil, Michael C. Wei, Shen Yin, Michelle Y. Doral, Chi-Chung Li, Huang Huang, Raluca Negricea, Elicia Penuel, Carol O'Hear, Nancy L. Bartlett
Journal: Blood
Blood (2021) 138 (Supplement 1): 127.
https://doi.org/10.1182/blood-2021-145872
Published: 2021
Journal Articles

Resistance of Natural Killer and T Cells to Venetoclax Allows for Combination Treatment with Cancer Immunotherapy Agents

Elisabeth A Lasater, PhD, An D Do, Luciana Burton, Yijin Li, Erin Williams, Jason Oeh, Luciana Molinero, Elicia Penuel, Deepak Sampath, Monique Dail, Marcia Belvin, Teiko Sumiyoshi, Elizabeth A Punnoose, Jeffrey Venstrom, Aparna Raval
Journal: Blood
Blood (2018) 132 (Supplement 1): 1118.
https://doi.org/10.1182/blood-2018-99-116405
Published: 2018
Journal Articles

Polatuzumab Vedotin (Pola) Plus Bendamustine (B) with Rituximab (R) or Obinutuzumab (G) in Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL): Updated Results of a Phase (Ph) Ib/II Study

Laurie H Sehn, MDMPH, Alex F. Herrera, MD, Matthew J Matasar, Manali Kamdar, Sarit Assouline, Mark Hertzberg, Tae Min Kim, Won-Seog Kim, Andrew McMillan, Muhit Özcan, Jamie M Hirata, Elicia Penuel, Ji Cheng, Grace Ku, Christopher R Flowers, MDMS
Journal: Blood
Blood (2018) 132 (Supplement 1): 1683.
https://doi.org/10.1182/blood-2018-99-118551
Published: 2018
Journal Articles

Addition of Polatuzumab Vedotin to Bendamustine and Rituximab (BR) Improves Outcomes in Transplant-Ineligible Patients with Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL) Versus BR Alone: Results from a Randomized Phase 2 Study

Laurie H. Sehn, MDMPH, Alex F. Herrera, MD, Matthew J. Matasar, MD, Manali Kamdar, Andrew K. McMillan, FRCP, Tae Min Kim, Won Seog Kim, MD, Ph. D., Mark Hertzberg, MBBS, PhD, Muhit Ozcan, MD, Elicia Penuel, Ji Cheng, Jamie M. Hirata, Grace Ku, Christopher Flowers, MD
Journal: Blood
Blood (2017) 130 (Supplement 1): 2821.
https://doi.org/10.1182/blood.V130.Suppl_1.2821.2821
Published: 2017